All In Biotech

Drug Trial Radar · NCT04259164

Anti-inflammatory Effects Glycopyrronium

Evaluation of the Anti-inflammatory Effects of Glycopyrronium Added to Indacaterol/Mometasone on the Allergen-induced Late Asthmatic Response

Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

28

Actual

Start

Sep 10, 2020

Primary completion

Dec 29, 2022

Study completion Dec 29, 2022

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Feb 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double-blind, randomized, two-way cross-over study with two treatment periods. 28 subjects with asthma will be randomized in 1:1 ratio to treatment A) Indacaterol/Mometasone 150/160 μg once daily and treatment B) Indacaterol/Glycopyrronium/Mometasone 150/50/80 μg once daily for period 1. For period 2, subjects will be crossed over to the other treatment arm. Subjects will be screened during the first visit. After inclusion subjects will be seen for 3 visits during the Run-in period, 3 visits during treatment period 1 and 3 visits during treatment period 2. During these visits patients will be clinically characterized and exposed to allergen challenge tests.

Conditions

  • Asthma
  • Allergic Asthma

Interventions

  • QVM149Drug

    Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol

  • QMF149Drug

    Mometasone / Indacaterol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % of sputum eosinophilsTime frame: 24 hours after allergen challenge at the end of each treatment period vs. control allergen challenge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Groningen

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.